All Blogs
May 17, 2024
GSK and iTeos Alliance Boosts Belrestotug Prospects in TIGIT Space
iTeos shares jump by 40%. GSK and iTeos collaboration for Belrestotug looks like a worthy wait. Hopes to ward off the negative sentiments around the volatile TIGIT space? In the ever-evolving landscape of cancer immunotherapy, the pursuit of effective treatment strategies continues to drive innovation and invest...
Read More...
May 16, 2024
Siemens Healthineers USD 314 Million Investment; Samsung Medison’s Sonio Acquisition; Leo Cancer Care’s Upright Technology Clearance; OrthoXel’s Vertex Hip Fracture Nail FDA 510 (k) Clearance; SPR Therapeutics’ PNS Pain Relief Device Positive Data; Valneva’s Chikungunya Vaccine Positive Pivotal Phase III Data
Siemens Healthineers Invested USD 314 Million in New MRI Manufacturing Plant On May 15, 2024, Siemens Healthineers announced that it had invested USD 314 million in a new MRI manufacturing plant in the UK. The facility in Oxford, England, which Siemens anticipates opening in 2026, will develop technology to redu...
Read More...
Jun 06, 2025
The Rise of Sleep Tech Devices: Unlocking Better Sleep
In today’s fast-paced world, achieving quality rest can be challenging—this is where sleep tech devices are making a difference. Leveraging innovative sleep trackers for detailed insights and smart tech for better sleep, the latest sleep technology products help users monitor and enhance their sleep patterns. From ...
Read More...
May 14, 2024
Takeda and AC Immune’s Alzheimer’s Deal; Eli Lilly’s Donanemab FDA Review; Bristol Myers Squibb’s Phase III CheckMate -73L Trial Result; Regeneron Pharmaceuticals’ Dupixent sBLA; Excision BioTherapeutics’ EBT-101 Phase I/II Trial Results
Takeda and AC Immune Ink Exclusive Deal for Active Immunotherapy in Alzheimer’s, Focusing on Amyloid Beta Takeda and AC Immune SA have unveiled an exclusive global option and licensing pact concerning AC Immune’s active immunotherapies directed at harmful variants of amyloid beta (Abeta), notably ACI-24.060, int...
Read More...
Jun 10, 2025
Bispecific and Trispecific Antibodies: Are They Better Than CAR-Ts?
CAR-T cell therapy has revolutionized the treatment of blood cancers, earning regulatory approval and delivering impressive results in hematologic malignancies. However, its success has not yet translated to solid tumors, where it continues to face significant challenges and limited long-term efficacy. As a result,...
Read More...
May 10, 2024
X4 Pharmaceuticals’ XOLREMDI for WHIM Syndrome: First Targeted Treatment
X4 Pharmaceuticals has gained approval for its first product, XOLREMDI (mavorixafor), marking its entrance into the commercial rare disease market. The FDA approved mavorixafor on April 29, 2024, specifically for patients aged 12 and above diagnosed with WHIM syndrome (characterized by warts, hypogammaglobulinemia,...
Read More...
May 09, 2024
Monteris Smallest Brain Laser Probe Launch; Vesica Health’s AssureMDx Test Launch; Anaut’s Eureka α Japanese Regulatory Approval; Geneoscopy’s Labcorp-Partnered Colon Cancer Test FDA Approval; Novel Omeza® OCM™ Diabetic Foot Ulcers Results; LEO Pharma Phase III Plaque Psoriasis Trial Results
Monteris Launched Smallest Brain Laser Probe on the Market On May 01, 2024, Monteris Medical launched the NeuroBlate® NB3™ FullFire® 1.6mm laser probe, the company’s latest product line innovation for use with their market-leading NeuroBlate System. The NB3 laser probe, which integrates Monteris' patented coo...
Read More...
May 08, 2024
Nanomedicine Market: Evaluating the Pioneering Innovations and Future Growth Prospects
Nanomedicine has witnessed a remarkable evolution over the past few years, revolutionizing the landscape of medical treatment and diagnosis. Advancements in nanotechnology have paved the way for the development of innovative drug delivery systems, diagnostic tools, and therapeutic agents at the nanoscale level. Thi...
Read More...
May 07, 2024
Boehringer Ingelheim’s Diabetic Macular Ischemia Study; Novartis’ Mariana Oncology Acquisition; Astellas and Poseida Therapeutics Partnership; Prime Medicine’s PM359 IND; Pfizer’s TIVDAK FDA Approval
Boehringer Ingelheim Announces Promising Findings From Groundbreaking Study on Diabetic Macular Ischemia Boehringer Ingelheim released encouraging results from the HORNBILL Phase I/IIa trial of BI 764524, marking the pioneering investigation into a potential therapy for individuals with diabetic macular is...
Read More...
May 06, 2024
FcRn Inhibitors for Autoimmune Disorders: A Promising Therapeutic Approach
Autoimmune disorders, a group of conditions where the immune system mistakenly attacks healthy cells, affect millions worldwide, often leading to debilitating symptoms and reduced quality of life. Traditional treatments for autoimmune disorders have primarily focused on suppressing the immune system, which can leav...
Read More...